The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor
In this discussion, Chaitanya Acharya, PhD, and George Mulligan, PhD, Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, discuss an arm of the MyDRUG umbrella trial (NCT03732703), which is investigating genomically-guided treatment of patients with multiple myeloma (MM). In this arm, patients harboring activating RAF and RAS mutations were treated with the MEK inhibitor cobimetinib, and single-cell analyses of their bone marrow (BM) immune microenvironment were performed to identify any patterns arising as a result of MEK inhibition. Dr Mulligan also comments on the importance of immune science, as understanding the clinical outcomes of patients in the context of the health of their immune system will allow for therapy to be optimized. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
